Levodopa: From Biological Significance to Continuous Monitoring

Overview

Journal ACS Sens

Publisher American Chemical Society

Specialty Biotechnology

Date 2024 Jul 24

PMID 39047295

Authors

David Probst

Kartheek Batchu

John Robert Younce

Koji Sode

Affiliations

Soon will be listed here.

Abstract

A continuous levodopa sensor can improve the quality of life for patients suffering with Parkinson's disease by enhancing levodopa titration and treatment effectiveness; however, its development is currently hindered by the absence of a specific levodopa molecular recognition element and limited insights into how real-time monitoring might affect clinical outcomes. This gap in research contributes to clinician uncertainty regarding the practical value of continuous levodopa monitoring data. This paper examines the current state of levodopa sensing and the inherent limitations in today's methods. Further, these challenges are described, including aspects such as interference from the metabolic pathway and adjunct medications, temporal resolution, and clinical questions, with a specific focus on a comprehensive selection of molecules, such as adjunct medications and structural isomers, as an interferent panel designed to assess and validate future levodopa sensors. We review insights and lessons from previously reported levodopa sensors and present a comparative analysis of potential molecular recognition elements, discussing their advantages and drawbacks.

References

Yugender Goud K, Moonla C, Mishra R, Yu C, Narayan R, Litvan I . Wearable Electrochemical Microneedle Sensor for Continuous Monitoring of Levodopa: Toward Parkinson Management. ACS Sens. 2019; 4(8):2196-2204. DOI: 10.1021/acssensors.9b01127. View

Olanow C, Gauger L, Cedarbaum J . Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease. Ann Neurol. 1991; 29(5):556-9. DOI: 10.1002/ana.410290516. View

Moon J, Teymourian H, De la Paz E, Sempionatto J, Mahato K, Sonsa-Ard T . Non-Invasive Sweat-Based Tracking of L-Dopa Pharmacokinetic Profiles Following an Oral Tablet Administration. Angew Chem Int Ed Engl. 2021; 60(35):19074-19078. PMC: 8373796. DOI: 10.1002/anie.202106674. View

Omidvar A, Amanati Shahri A, Serrano A, Gruber J, Pamplona Rehder G . A Highly Sensitive Molecularly Imprinted Polymer (MIP)-Coated Microwave Glucose Sensor. Sensors (Basel). 2022; 22(22). PMC: 9694762. DOI: 10.3390/s22228648. View

Arroyo-Curras N, Somerson J, Vieira P, Ploense K, Kippin T, Plaxco K . Real-time measurement of small molecules directly in awake, ambulatory animals. Proc Natl Acad Sci U S A. 2017; 114(4):645-650. PMC: 5278471. DOI: 10.1073/pnas.1613458114. View

Daubner S, Le T, Wang S . Tyrosine hydroxylase and regulation of dopamine synthesis. Arch Biochem Biophys. 2010; 508(1):1-12. PMC: 3065393. DOI: 10.1016/j.abb.2010.12.017. View

Kaakkola S, Mannisto P, Nissinen E, Vuorela A, Mantyla R . The effect of an increased ratio of carbidopa to levodopa on the pharmacokinetics of levodopa. Acta Neurol Scand. 1985; 72(4):385-91. DOI: 10.1111/j.1600-0404.1985.tb00888.x. View

Black K, Acevedo H, Koller J . Dopamine Buffering Capacity Imaging: A Pharmacodynamic fMRI Method for Staging Parkinson Disease. Front Neurol. 2020; 11:370. PMC: 7232584. DOI: 10.3389/fneur.2020.00370. View

Irace C, Cutruzzola A, Nuzzi A, Assaloni R, Brunato B, Pitocco D . Clinical use of a 180-day implantable glucose sensor improves glycated haemoglobin and time in range in patients with type 1 diabetes. Diabetes Obes Metab. 2020; 22(7):1056-1061. PMC: 7317779. DOI: 10.1111/dom.13993. View

10.

Bergamini M, Santos A, Stradiotto N, B Zanoni M . A disposable electrochemical sensor for the rapid determination of levodopa. J Pharm Biomed Anal. 2005; 39(1-2):54-9. DOI: 10.1016/j.jpba.2005.03.014. View

11.

Heikkinen H, Varhe A, Laine T, Puttonen J, Kela M, Kaakkola S . Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose. Br J Clin Pharmacol. 2002; 54(4):363-71. PMC: 1874436. DOI: 10.1046/j.1365-2125.2002.01654.x. View

12.

Yoo S, Kim J, Yoo J, Yun E, Yoon U, Shin N . Delayed orthostatic hypotension in Parkinson's disease. NPJ Parkinsons Dis. 2021; 7(1):37. PMC: 8047032. DOI: 10.1038/s41531-021-00181-y. View

13.

Contin M, Martinelli P . Pharmacokinetics of levodopa. J Neurol. 2010; 257(Suppl 2):S253-61. DOI: 10.1007/s00415-010-5728-8. View

14.

Marino S, Sessa E, Di Lorenzo G, Digangi G, Alagna A, Bramanti P . Sertraline in the treatment of depressive disorders in patients with Parkinson's disease. Neurol Sci. 2008; 29(6):391-5. DOI: 10.1007/s10072-008-1021-3. View

15.

Dauphin-Ducharme P, Yang K, Arroyo-Curras N, Ploense K, Zhang Y, Gerson J . Electrochemical Aptamer-Based Sensors for Improved Therapeutic Drug Monitoring and High-Precision, Feedback-Controlled Drug Delivery. ACS Sens. 2019; 4(10):2832-2837. PMC: 6886665. DOI: 10.1021/acssensors.9b01616. View

16.

Ferreira J, Poewe W, Rascol O, Stocchi F, Antonini A, Moreira J . Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease. Mov Disord. 2022; 37(11):2272-2283. DOI: 10.1002/mds.29193. View

17.

Lee I, Probst D, Klonoff D, Sode K . Continuous glucose monitoring systems - Current status and future perspectives of the flagship technologies in biosensor research. Biosens Bioelectron. 2021; 181:113054. DOI: 10.1016/j.bios.2021.113054. View

18.

Wade L, Katzman R . Synthetic amino acids and the nature of L-DOPA transport at the blood-brain barrier. J Neurochem. 1975; 25(6):837-42. DOI: 10.1111/j.1471-4159.1975.tb04415.x. View

19.

Damier P, Hirsch E, Agid Y, Graybiel A . The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain. 1999; 122 ( Pt 8):1437-48. DOI: 10.1093/brain/122.8.1437. View

20.

Bailey T, Bode B, Christiansen M, Klaff L, Alva S . The Performance and Usability of a Factory-Calibrated Flash Glucose Monitoring System. Diabetes Technol Ther. 2015; 17(11):787-94. PMC: 4649725. DOI: 10.1089/dia.2014.0378. View